Dexmethylphenidate: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [pending revision] |
MDElliottMD (talk | contribs) Pharmacopedia: add <pharmaInteractions/> |
MDElliottMD (talk | contribs) Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 15: | Line 15: | ||
| legal = Schedule II | | legal = Schedule II | ||
| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical indications, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate. | | intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical indications, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate. | ||
| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated | | pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect. | ||
| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors. | | pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors. | ||
| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults) | | indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults) | ||
| Line 78: | Line 78: | ||
* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence | * At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence | ||
* Sleep quality and timing of last dose | * Sleep quality and timing of last dose | ||
* Periodically reassess continued need; consider | * Periodically reassess continued need; consider med holidays in children | ||
| counseling = * Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia. | | counseling = * Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia. | ||
* '''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.''' | * '''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.''' | ||
| Line 92: | Line 92: | ||
| references = | | references = | ||
}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span> | }}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span> | ||
'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated | '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2> | ||
Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Indications">Indications</h2> | Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Indications">Indications</h2> | ||
*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults) | *Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults) | ||
| Line 165: | Line 165: | ||
*At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence | *At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence | ||
*Sleep quality and timing of last dose | *Sleep quality and timing of last dose | ||
*Periodically reassess continued need; consider | *Periodically reassess continued need; consider med holidays in children<h2 id="Counseling">Patient counseling</h2> | ||
*Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia. | *Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia. | ||
*'''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.''' | *'''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.''' | ||
| Line 179: | Line 179: | ||
''The following are personal accounts and not medical advice.'' | ''The following are personal accounts and not medical advice.'' | ||
<span></span><discuss slug="personal-experience" /> | <span></span><discuss slug="personal-experience" /> | ||
[[Category:Stimulants]] | |||
[[Category:Methylphenidates (Phenidates)]] | |||